Clinical Trials
Multiple late-stage Phase 3 clinical trials sponsored by Merck Sharp & Dohme LLC have completed recruitment evaluating sugammadex in general anesthesia settings. These studies investigated the agent's efficacy, safety, and pharmacokinetic profile for reversing neuromuscular blockade, including comparative evaluations and assessments in subjects with normal or impaired renal function. Overall, these clinical investigations emphasize the therapeutic focus on optimizing recovery from neuromuscular blockade in surgical patients.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00451100 | Completed | Anesthesia General |
Merck Sharp & Dohme LLC |
2005-11-10 | Phase 3 |
| NCT00482599 | Completed | Anesthesia General |
Merck Sharp & Dohme LLC |
2005-06-01 | Phase 3 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Sugammadex (sodium) Solubility in DMSO
- Sugammadex (sodium) Stock Solution
- Sugammadex (sodium) Storage
- Sugammadex (sodium) Stability
- Sugammadex (sodium) Molecular Weight
- Sugammadex (sodium) SMILES
- Sugammadex (sodium) CAS Number
- Sugammadex (sodium) Chemical Structure (2D and 3D)
- Sugammadex (sodium) SDS|MSDS